Added to YB: 2025-08-15
Pitch date: 2025-08-13
PRTA [bullish]
Prothena Corporation plc
+12.59%
current return
Author Info
BiotechBonanza shares takes on biotech with a heavy focus on special situations. Sign up for the newsletter.
Company Info
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
Market Cap
$482.3M
Pitch Price
$8.02
Price Target
242.00 (+2580%)
Dividend
N/A
EV/EBITDA
-0.73
P/E
-1.72
EV/Sales
13.62
Sector
Biotechnology
Category
special_situation
Prothena (PRTA): An absolute monster of a royalty stub in the making!
PRTA: Biotech in winddown trading at $411M mkt cap w/ $326M cash ($85M EV). Key assets: 2 Ph3 programs partnered w/ Roche & Novo (multi-billion indications), 2 w/ BMY. Upcoming milestones: $50M from Novo (2026), huge royalties possible. Prasinezumab (Roche) alone could be worth 3-5B if approved. Company plans shareholder returns. 20-30x potential if assets advance.
Read full article (12 min)